Key takeaways: Using NHANES data from 2017 to 2023, obesity prevalence in the U.S. is 75.2% when excess adiposity cutoffs are used. Among adults with a BMI of less …
✏️ ADMIN EDIT MODE local_hospital MedJournal dark_mode Research chevron_right Immunology Targeted Immunotherapy in Chronic Autoimmune Disorders A comprehensive analysis of novel monoclonal antibody treatments and their long-term efficacy in Phase …
y
Login/Sign Up – MedResearch Pro MedResearch Pro Research Pricing About Log In Sign Up menu Welcome to MedResearch Pro Join thousands of medical professionals advancing their knowledge. Continue with Google …
Login/Sign Up – MedResearch Pro MedResearch Pro Research Pricing About Log In Sign Up menu Welcome to MedResearch Pro Join thousands of medical professionals advancing their knowledge. Continue with Google …
Excerpt:
The FDA has granted approval to Novartis for Itvisma (onasemnogene abeparvovec-brve), the first gene replacement therapy for spinal muscular atrophy (SMA) available for patients aged 2 years and older. Backed by data from the Phase 3 STEER and Phase 3b STRENGTH trials, this one-time intrathecal treatment addresses the genetic root cause of SMA and is expected to be available in the U.S. this December.
Excerpt : Despite advances in technology, cardiovascular death rates remain stagnant. Interventional cardiologist Dr. Koushik Reddy argues for a radical paradigm shift—moving the foundation of care from the cath lab to the “kitchen table.” Learn how he uses the “CARROTS” framework to integrate lifestyle medicine into critical cardiac care.
Persistent maternal thyroid dysfunction—especially when it spans multiple trimesters—significantly increases the risk of autism in children. A 2.68-fold rise in autism diagnoses was observed in cases where thyroid imbalance occurred both before and during pregnancy, underscoring the need for careful monitoring and timely treatment adjustments.